Neurostimulation devices market seen hitting $29.72B by 2035

The global neurostimulation devices market is projected to nearly triple to $29.72 billion by 2035 from $11.13 billion in 2026, according to Market Research Future. Growth is being driven by rising neurological disease rates, wider reimbursement and faster adoption of closed-loop, AI-enabled implants across pain, Parkinson’s, depression and epilepsy care.

Why it matters: - The market’s forecast growth points to broader use of neurostimulation as insurers and health systems expand access to therapies for chronic pain, movement disorders and psychiatric conditions. - Faster adoption could shift neurostimulation from specialty use toward more routine care in hospitals, clinics and home settings. - The move toward closed-loop and AI-enabled systems may improve outcomes and reduce follow-up burden for patients and providers.

What happened: - Market Research Future said the global neurostimulation devices market is expected to rise from $11.13 billion in 2026 to $29.72 billion by 2035. - The firm put 2025 market size at $9.98 billion. - The forecast implies an 11.50% compound annual growth rate from 2026 to 2035. - The report was published June 15, 2026. - A free sample and detailed report are available from Market Research Future.

The details: - Rising neurological disease prevalence is a core growth driver, including Parkinson’s disease, dementia and chronic pain. - WHO data cited in the report puts global dementia cases at about 55 million in 2022, with nearly 10 million new cases annually. - The report says Parkinson’s disease incidence has doubled over the past 25 years, affecting more than 8.5 million people globally. - The International Association for the Study of Pain estimates one in five adults worldwide experiences chronic pain. - Closed-loop systems that adjust stimulation in real time based on neural biomarkers are replacing older open-loop devices. - Medtronic’s Percept PC and Abbott’s sensing algorithms showed 30% to 40% better symptom control for Parkinson’s patients than open-loop devices, according to the report. - The next-generation spinal cord stimulator pipeline drew more than $1.2 billion in venture and strategic capital from 2022 to 2024. - The report expects 60% of newly implanted deep brain stimulation systems to include embedded machine learning algorithms by 2030. - CMS expanded coverage for high-frequency spinal cord stimulation in 2023 for failed back surgery syndrome and complex regional pain syndrome. - Germany’s G-BA broadened statutory coverage for deep brain stimulation in treatment-resistant depression. - The UK’s NICE issued positive appraisals for high-frequency spinal cord stimulation, and the NHS Long Term Plan set aside funding for neurological care. - China’s Healthy China 2030 initiative, India’s Ayushman Bharat program and India’s Production Linked Incentive scheme are also supporting demand and manufacturing.

Between the lines: - Reimbursement changes matter because they lower out-of-pocket costs and make adoption easier for hospitals and physicians. - The report suggests the market is moving beyond pain management into psychiatry, where FDA breakthrough designations are expanding use cases for responsive neurostimulation. - The competitive edge is shifting toward devices with sensing, software and remote programming features rather than hardware alone. - The report’s regional breakdown shows North America leads on reimbursement depth, Europe on favorable health technology assessments and Asia-Pacific on growth speed. - Low market concentration leaves room for incumbents, startups and broader medtech players to compete for share.

What’s next: - The report expects AI-driven adaptive stimulation to become the standard by 2030. - It also forecasts that 40% of device revenue could come from software and services by 2030, compared with one-time hardware sales. - Specialty clinics and home-care use could expand as non-invasive vagus nerve and transcranial stimulation devices win clearer regulatory pathways. - China and India are expected to remain major demand centers in Asia-Pacific, while Saudi Arabia, Brazil and the U.S. anchor regional growth elsewhere.

The bottom line: - Neurostimulation devices are moving from niche implants to a larger, data-driven treatment platform, with reimbursement and AI-enabled features likely to determine the winners.